Invention Grant
- Patent Title: Regimes of FXR agonists
-
Application No.: US16333030Application Date: 2017-09-12
-
Publication No.: US11052069B2Publication Date: 2021-07-06
- Inventor: Bryan Laffitte , Andreas Bauer , Michael Badman , Jin Chen , Patrick Mueller , Rachel Soon
- Applicant: NOVARTIS AG
- Applicant Address: CH Basel
- Assignee: NOVARTIS AG
- Current Assignee: NOVARTIS AG
- Current Assignee Address: CH Basel
- Agency: Novartis Institues for BioMedical Reseach, Inc.
- Agent Emily T. Wu
- International Application: PCT/IB2017/055501 WO 20170912
- International Announcement: WO2018/051229 WO 20180322
- Main IPC: A61K31/4162
- IPC: A61K31/4162 ; A61K31/4178 ; A61P1/16 ; A61K9/00 ; A61K31/55 ; A61K45/06
Abstract:
The invention provides novel regimens of farnesoid X receptor (FXR) agonist and methods for modulating the activity of farnesoid X receptors (FXRs) using novel regimes of specific FXR agonists, in particular for treating or preventing fibrotic or cirrhotic diseases or disorders, such as liver diseases.
Public/Granted literature
- US20190262313A1 NOVEL REGIMES OF FXR AGONISTS Public/Granted day:2019-08-29
Information query
IPC分类:
